Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo
Yong Tao(Shanghai Ninth People's Hospital), Zheng‐Yi Chen(Massachusetts Eye and Ear Infirmary), Xue Gao(Xijing Hospital), Verónica Lamas(Massachusetts Eye and Ear Infirmary), Wenliang Zhu(Kyoto Institute of Technology), John A. Zuris(Howard Hughes Medical Institute), Wan Du(University of Michigan), Weijia Kong(Wuhan Union Hospital), Johnny H. Hu(Howard Hughes Medical Institute), Benjamin P. Kleinstiver(Harvard University), David R. Liu(Broad Institute), Hao Wu(Shanghai Jiao Tong University), Yilai Shu(Fudan University), Charles Pei(Massachusetts Eye and Ear Infirmary), Yiran Li(Morinaga (Japan)), David B. Thompson(Howard Hughes Medical Institute), Madelynn N. Whittaker(Cardiovascular Institute of the South), Xuezhong Liu(University of Miami), Arun Prabhu Rameshbabu(Massachusetts Eye and Ear Infirmary)
Cited by 49
Related Papers
High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects
|Nature|2016|2.7k
CRISPResso2 provides accurate and rapid genome editing sequence analysis
|Nature Biotechnology|2019|1.8k
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
|Nature|2015|1.7k
Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo
|Nature Biotechnology|2014|1.5k